Antigen-specific Induction of Immune Tolerance

The goal of Topas (Tolerizing Particles) is to develop novel therapeutics to treat a variety of immune-mediated and autoimmune diseases. The Topas approach harnesses the natural mechanisms of the liver to promote immune tolerance to blood borne antigens. Small peptide-loaded nanoparticles mimic such blood borne antigens and are taken up by liver sinusoidal endothelial cells (LSECs). LSECs present these antigens to T cells under anti-inflammatory conditions conducive to the induction of tolerogenic regulatory T cells (Tregs).

Tregs are pivotal for immune tolerance, and their therapeutic generation serves to re-instate healthy immune homeostasis and provide a cure for diseases characterized by undesirable or dysregulated inflammatory immune reactions.

Latest News

2017-11-02 – Press release

Topas Therapeutics extends its Series A to EUR 18 Million (USD 21 Million) with Boehringer Ingelheim Venture Fund

read more …

2017-10-26 – Press release

Topas Therapeutics Appoints Rupert Sandbrink, M.D., Ph.D., as Chief Development Officer and Chief Medical Officer

read more …

2017-08-22 – Press release

Topas Therapeutics signs multi-year research and option agreement with Lilly focused on immune tolerance

read more …

2017-04-04 – Press release

Paul Sekhri joins Topas Therapeutics as Chairman of the Board

read more …

2016-03-22 – Press release

Evotec spins off auto-immune disease company as ‘Topas Therapeutics GmbH’

read more …